A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05453825

Public ClinicalTrials.gov record NCT05453825. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: * Cohort A: CRC * Cohort B: Gastric and GEJ cancer * Cohort C: TNBC * Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)

Study identification

NCT ID: NCT05453825
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: OncXerna Theraputics, Inc.; Industry
Enrollment: 180 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 5, 2022 (Actual)
Primary completion: Apr 15, 2024 (Estimated)
Completion: Dec 15, 2024 (Estimated)
Last update posted: Jan 31, 2023

2022 – 2024

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Genesis Cancer Center	Hot Springs	Arkansas	71913	Recruiting
Keck Medicine of USC	Los Angeles	California	90033	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Northside Hospital	Atlanta	Georgia	30322	Recruiting
Hematology Oncology Clinic	Baton Rouge	Louisiana	70809	Recruiting
New York University - Langone Health - Perlmutter Cancer Center	New York	New York	10016	Recruiting
The Zangmeister Cancer Center	Columbus	Ohio	43219	Recruiting
Tennessee Oncology	Nashville	Tennessee	37203	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05453825, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 31, 2023 · Synced Nov 3, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05453825 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →